Scarica l'app Stockscreener
5.28
0.19%
0.01
Dopo l'orario di chiusura:
5.31
0.03
+0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$5.27
Aprire:
$5.29
Volume 24 ore:
3.69M
Relative Volume:
1.19
Capitalizzazione di mercato:
$550.93M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-3.2195
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-5.88%
1M Prestazione:
+26.62%
6M Prestazione:
-23.70%
1 anno Prestazione:
-41.53%
Intervallo 1D:
$5.1699
$5.50
Intervallo di 1 settimana:
$5.1699
$6.0299
Portata 52W:
$2.90
$9.59
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.28 | 549.88M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
EBITDA per share of Altimmune, Inc. – LS:A2N5Z6 - TradingView — Track All Markets
Retail Surge: Why Altimmune Inc stock remains on buy listsJuly 2025 Levels & Real-Time Price Movement Reports - moha.gov.vn
Altimmune (NASDAQ:ALT) Stock Price Up 12.2%Here's Why - MarketBeat
Published on: 2025-12-14 03:05:57 - moha.gov.vn
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts - ts2.tech
Altimmune Amends Loan Agreement with Hercules Capital - MSN
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Zacks Investment Research
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineALT - ACCESS Newswire
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025 - ts2.tech
Altimmune Inc (NASDAQ:ALT) Ownership - Morningstar Australia
Altimmune Inc (NASDAQ:ALT) Valuation - Morningstar Australia
Altimmune Inc (HAM:3G0) Competitors 2025 - GuruFocus
Altimmune (HAM:3G0) ROA % : -36.91% (As of Sep. 2025) - GuruFocus
Altimmune (HAM:3G0) EV-to-EBIT : -4.00 (As of Dec. 08, 2025) - GuruFocus
Altimmune Inc (HAM:3G0) Stock Price, Trades & News - GuruFocus
Geode Capital Management LLC Raises Holdings in Altimmune, Inc. $ALT - MarketBeat
Altimmune: 48-Week MASH Data Due This Month Is Make Or Break For The Company (NASDAQ:ALT) - Seeking Alpha
EBITDA per share of Altimmune, Inc. – LSE:0A4C - TradingView
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down - geneonline.com
Altimmune (ALT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Durso succeeding Garg as Altimmune CEO - BioCentury
Altimmune releases additional phase 2 pemvidutide data for MASH - MSN
Altimmune (NASDAQ:ALT) Stock Price Down 6.6%Time to Sell? - MarketBeat
Investors SueWallSt as Altimmune, Inc. Faces Securities Fraud Allegations - The National Law Review
ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan
Altimmune Announces CEO Transition and Succession Plan - The Globe and Mail
Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending - TradingView
Altimmune announces CEO transition - MSN
Gaithersburg drug developer Altimmune names new CEO as current chief readies exit - The Business Journals
Altimmune stock falls after CEO Garg announces 2026 departure By Investing.com - Investing.com Canada
Altimmune stock falls after CEO Garg announces 2026 departure - Investing.com
Altimmune, Inc. Announces CEO Changes - marketscreener.com
Altimmune CEO Vipin Garg to Step Down - marketscreener.com
Altimmune names Jerry Durso as new CEO effective January 2026 By Investing.com - Investing.com Canada
Altimmune, Inc. Announces CEO Transition - TradingView
Altimmune names Jerry Durso as new CEO effective January 2026 - Investing.com
Altimmune (ALT) Announces CEO Transition Plan - GuruFocus
Altimmune falls as CEO Vipin Garg to step down - TradingView
Altimmune announces leadership change as CEO Vipin Garg steps down - Traders Union
Altimmune, Inc. Announces CEO Transition as Jerry Durso Succeeds Vipin Garg, Ph.D. - Quiver Quantitative
Altimmune announces CEO transition, succession plan - marketscreener.com
Altimmune Announces CEO Transition, Succession Plan - TradingView — Track All Markets
Altimmune (Nasdaq: ALT) details CEO handover and late-stage pemvidutide path in MASH - Stock Titan
Intech Investment Management LLC Purchases 73,482 Shares of Altimmune, Inc. $ALT - MarketBeat
Altimmune Investors Drop Suit Over Liver Drug Trial, Stock Drop - Bloomberg Law News
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Altimmune (Nasdaq: ALT) to Present Chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - MSN
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment - ts2.tech
Altimmune’s RECLAIM STUDY: A New Hope for Alcohol Use Disorder Treatment - MSN
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):